Envestnet Asset Management Inc. Sells 2,686 Shares of Biogen Inc. $BIIB

Envestnet Asset Management Inc. reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 53,390 shares of the biotechnology company’s stock after selling 2,686 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Biogen were worth $7,479,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in BIIB. Vanguard Group Inc. increased its stake in shares of Biogen by 1.5% during the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock valued at $2,171,533,000 after buying an additional 257,812 shares during the period. State Street Corp grew its holdings in Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after acquiring an additional 71,897 shares in the last quarter. Geode Capital Management LLC increased its position in Biogen by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock valued at $490,089,000 after purchasing an additional 71,286 shares during the period. Invesco Ltd. increased its position in Biogen by 2.4% during the 2nd quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company’s stock valued at $291,385,000 after purchasing an additional 55,119 shares during the period. Finally, Norges Bank bought a new stake in shares of Biogen in the 2nd quarter valued at about $284,358,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Stock Down 0.0%

NASDAQ:BIIB opened at $192.03 on Friday. The company has a market cap of $28.18 billion, a PE ratio of 21.80, a P/E/G ratio of 1.52 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The company’s 50 day moving average is $180.02 and its two-hundred day moving average is $161.10.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the business posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Stifel Nicolaus increased their target price on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. UBS Group began coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price target on the stock. HSBC reissued a “reduce” rating and issued a $143.00 price target (down from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Finally, Wedbush raised their price objective on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, Biogen currently has an average rating of “Hold” and an average price target of $205.04.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.